Elanco Animal Health Incorporated (ELAN)
- Previous Close
14.47 - Open
14.45 - Bid --
- Ask 15.75 x 1100
- Day's Range
14.50 - 14.65 - 52 Week Range
8.52 - 18.80 - Volume
20,173 - Avg. Volume
5,314,291 - Market Cap (intraday)
7.227B - Beta (5Y Monthly) 1.40
- PE Ratio (TTM)
-- - EPS (TTM)
-2.55 - Earnings Date Nov 5, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.23
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
www.elanco.com9,300
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ELAN
View MorePerformance Overview: ELAN
Trailing total returns as of 9/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ELAN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ELAN
View MoreValuation Measures
Market Cap
7.15B
Enterprise Value
12.41B
Trailing P/E
--
Forward P/E
13.77
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.59
Price/Book (mrq)
1.20
Enterprise Value/Revenue
2.76
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-27.94%
Return on Assets (ttm)
1.30%
Return on Equity (ttm)
-18.78%
Revenue (ttm)
4.49B
Net Income Avi to Common (ttm)
-1.26B
Diluted EPS (ttm)
-2.55
Balance Sheet and Cash Flow
Total Cash (mrq)
416M
Total Debt/Equity (mrq)
95.52%
Levered Free Cash Flow (ttm)
175.12M